Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study

INTRODUCTION: In patients with relapsed SCLC, amrubicin (AMR) is the current standard treatment in Japan. Nevertheless, its efficacy is not satisfactory and prognosis is poor. Preclinical study suggested that anthracycline agent might induce immunogenic cell death and work synergistically with immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamatsu, Hiroaki, Teraoka, Shunsuke, Hayashi, Hidetoshi, Fujimoto, Daichi, Hayata, Atsushi, Haratani, Koji, Ozawa, Yuichi, Yoshida, Takeshi, Iwasa, Tsutomu, Shimokawa, Toshio, Tomii, Keisuke, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474202/
https://www.ncbi.nlm.nih.gov/pubmed/34590034
http://dx.doi.org/10.1016/j.jtocrr.2021.100184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474202/
https://www.ncbi.nlm.nih.gov/pubmed/34590034
http://dx.doi.org/10.1016/j.jtocrr.2021.100184

Ejemplares similares